Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta



Register
Login:
Share:
Email Facebook Twitter

TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake Watch Now

TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake
Exclusive: Hardman & Co Investor Forum - Severn Trent, Calculus Capital, Volta Finance, Residential


Motif Bio Share Chat (MTFB)



Share Price: 3.175Bid: 3.05Ask: 3.30Change: 0.00 (0.00%)No Movement on Motif Bio
Spread: 0.25Spread as %: 8.20%Open: 3.25High: 0.00Low: 0.00Yesterday’s Close: 3.175


Share Discussion for Motif Bio




View all MTFB Messages

Please login or register to post a message on Share Chat.

Posts per page:

InvestingWizard
Posts: 87
Opinion:No Opinion
Price:7.40
Questions to Ask at AGM
22 May '19
1) During the Revive I and II trials, did MTFB conduct liver function tests: A) at the end of treatment (EOT) visit, B) at the test of cure (TOC) visit (7 to 14 days after the EOT), and C) at the late follow-up (LFU visit)?

2) If they answer yes, how did the results compare to the Assist I and II trials? In particular, did the AST/ALT levels of a set number of subject continue to increase between end of treatment (EOT) and late follow-up visit?

3) If they say the question lacks relevance, ask them why they went to great length to discuss the Assist trials liver toxicity data in the 2019 20-F (SEC Annual Report) but not in the 2018 20-F? Then proceed with repeating questions 1 and 2 back to them.

4) If they say they did not re-perform the same liver toxicity studies for the Revive I and II trials, ask them how could they not have re-performed the studies since Arpida could not explain the reasons behind increases in ALT values developing after stopping iclaprim?

5) If they say the fixed-dose regimen used in Revive I and II trials resolved all previously reported liver toxicity problems, ask them how could they be comfortable with the safety profile of the new dose regimen if they did not re-perform the same liver function tests they conducted during the Assist I and II trials?




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.